We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
- Authors
Ko, Andrew H; Venook, Alan P; Bergsland, Emily K; Kelley, R Kate; Korn, W Michael; Dito, Elizabeth; Schillinger, Brian; Scott, Janet; Hwang, Jimmy; Tempero, Margaret A
- Abstract
No standard of care exists for patients with metastatic pancreatic cancer following progression on first-line chemotherapy. Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population.
- Publication
Cancer chemotherapy and pharmacology, 2010, Vol 66, Issue 6, p1051
- ISSN
1432-0843
- Publication type
Journal Article
- DOI
10.1007/s00280-010-1257-5